Xinkun^® Sodium Valproate Concentrated Solution for Injection is a classic broad-spectrum anti-epileptic drug. It exerts its anti-epileptic effect by increasing the content of γ-aminobutyric acid (GABA) and inhibiting voltage-sensitive Na+ channels, preventing abnormal discharges, and thus effectively treating various types of epilepsy. Xinkun^® was approved for marketing as a Class 3 chemical drug in March 2023. It is included in the eighth batch of the National Drug Centralized Procurement Program and is listed as a Category B drug in the National Medical Insurance Catalog. Sodium Valproate Concentrated Solution for Injection is rapidly absorbed and acts quickly, reaching steady-state blood concentrations rapidly. It is suitable for various types of epilepsy seizures during the perioperative period and is a first-line treatment recommended by major domestic and international guidelines.